Programme Supplement [International Conference on AIDS (16th: 2006: Toronto, Canada)]

Introduction

Thursday 17 August
Late Breaker Abstracts 16:15- 17:45

14:45
THLBO213
/
14:55
THLBO214

Thursday

15:05
THLBO215
15:15
THLBO216
15:25
THLB0217

Predictors of virologic failure and HIV
drug resistance among patients receiving
fixed dose combination stavudine/
lamivudine/nevirapine in northern
Tanzania
H.O. Ramadhani', N.M. Thielman2, F. Gao2,
J. Kirchherr2, R. Shah2, K.Z. Landman2, E.M.
Ndosi', H.J. Shao', S.C. Morpeth2, J. McNeillP,
V.P. Maro', J.F. Shao', J.A. Bartlett2, J.A.
Crump2
'Tanzania, United Republic of, 2United States
Potent antiretroviral effect of MK-0518,
a novel HIV-1 integrase inhibitor, as part
of combination ART in treatment -naive
HIV-1 infected patients
M. Markowitz', B.-Y. Nguyen', F. Gotuzzo2,
F. Mendo2, W. Ratanasuwan3, C. Kovacs4, J.
Zhao', L. Gilde', R. Isaacs', H. Teppler'
'United States, 2Peru, 3Thailand, 4Canada
Safety and Efficacy of Maravirbc (MVC),
a Novel CCR5 Antagonist, When Used in
Combination with Optimized Background
Therapy (OBT) for the Treatment of
Antiretroviral-Experienced Subjects
Infected with Dual/Mixed-Tropic HIV-1:
24-Week Results of a Phase 2b
H. Mayer', E. van der Ryst2, M. Saag', B.
Clotet3, G. Fatkenheuer4, N. Clumecks, K.
Turner2, J.M. Goodrich'
'United States, 2United Kingdom, 3Spain,
4Germany, sBelgium
A phase I study to explore the safety,
tolerability, and pharmacokinetics of
Fosalvudine Tidoxil in patients infected
with HIV-1
P. Cahn', F. Reuss2, M. Rolon1, F. Wit3, E.
Boehm2, J. Lange3
'Argentina, 2Germany, 3Netherlands
ACTG 5211: phase II study of the safety
and efficacy of vicriviroc in HIV-infected
treatment-experienced subjects
R. Gulick, Z. Su, C. Flexner, M. Hughes, P.
Skolnik, C. Godfrey, W. Greaves, T. Wilkin,
R. Gross, E. Coakley, A. Zolopa, M. Hirsch, D.
Kuritzkes, for the ACTG 5211 Study Team
United States,
TNX-355, in Combination with Optimized
Background Regimen (OBR), Achieves
Statistically Significant Viral Load
Reduction and CD4 Cell Count Increase
When Compared with OBR alone in
Phase 2 study at 48 Weeks
D. Norris', J. Morales2, E. Godofsky', F.
Garcia', R. Hardwicke', S. Lewis'
'United States, 2Puerto Rico

Venue:
Date:
Time:
Chairs:
16:15
THLBO301
16:25
THLBO302
16:35
THLBO303
16:45
THLBO304
16:55
THLBO305
17:05
THLBO306
17:15
THLBO307

THLBO3 Late Breaker Track A

Es
EM
Mffilated
Evnt

Abstract Session
Session Room 7, Level 700
Thursday 17 August
16:15-17:45
Jean-Francois Delfraissy, France
Marisa Morgado, Brazil
HIV neutralizing IgA in the genital tract
of high-risk Kenyan sex workers is
prospectively associated with protection
against sexual acquisition of HIV
T. Hirbod', R. KauPl, C. Reichard', J. Kimani3,
E. Ngugi', J. Bwayo3, N. Nagelkerke2, S.
Moses2, K. MacDonald2, K. Broliden', The
Kibera HIV Study Group
'Sweden, 2Canada, 3Kenya,
Preservation of a subset of SIV-specific
CD4+ T cells with central memory
markers correlates to control of viremia
in SIVmac251 infected macaques
A. von Gegerfelt, A. Valentin, V. Patel, M.
Rosati, C. Alicea, M. Morrow, B. Felber, G.
Pavlakis
United States
CXCR4-Utilizing HIV-1 strains activate
innate immunity via CD14 and toll-like
receptor 2
H. Zhu, R.C. Huard, M. Nociari, T. He, K.
Zerria, Z. Chen, D. Golenbock, J.L. Ho, AIDS
pathogenesis, Immunology, innate immunity
United States,
Proteo-liposomes as a new drug delivery
system to HIV reservoir cells and free
virion entrapment
T. Bronshtein S. Pollack, M. Machluf
Israel
Drug candidate TAT0002, a telomerase
activator, enhances antiviral functions of
HIV-1-specific CD8 T-cells
C.B. Harley, S.R. Fauce, A.C. Chin, B.D.
Jamieson, 0.0. Yang, R.B. Effros
United States
The HIV-1 envelope gene determines
viral fitness in both drug sensitive and
resistant isolates
I. Nankya, A. Abraha, E. Fraundorf,
A. Marozsan, Y. Gao, B. Johnston, D.
Katzenstein, E. Arts
United States
A bioinformatic approach to study
escape mutations of HIV-1: analysis of
gag genes
H. Peters', M. Mendoza', R. Capina', M. Luo',
X. Mao', M.J. Gubbins', I. MacArthur', B.B.
Sheardown', J. Kimani2, J. Ndinya-Achola2,
S. Njenga2, J.B. Bwayo2, S. Thavaneswaran',
F.A. Plummer'
'Canada, 'Kenya

15:35
THLBO218

XVI INTERNATIONAL AIDS CONFERENCE * 13-18 AUGUST 2006 * TORONTO CANADA'. PROGRAMME SUPPLEMENT